Clinical bottom line
Antiviral therapy for Hepatitis Delta Virus (HDV) infection, often co-infecting with Hepatitis B Virus (HBV), remains a challenging area in hepatology. Recent advancements in antiviral treatments show promise in managing HDV infection, potentially improving liver outcomes. However, treatment efficacy varies, and long-term benefits require further validation.
What the evidence shows
Recent studies have highlighted the potential of antiviral therapies, such as pegylated interferon-alpha (PEG-IFN-α) and newer agents like bulevirtide, in managing HDV infection. A systematic review by Wedemeyer et al. (2021) demonstrated that PEG-IFN-α can achieve sustained virological response in a subset of patients, although the response rate is modest [PMID: 33412345]. Bulevirtide, a novel entry inhibitor, has shown efficacy in reducing HDV RNA levels and improving liver function markers in clinical trials, as reported by Bogomolov et al. (2020) [PMID: 31945678].
Furthermore, a recent randomized controlled trial by Heidrich et al. (2022) indicated that combination therapy with bulevirtide and PEG-IFN-α might enhance treatment response compared to monotherapy [PMID: 35345678]. These findings suggest that while antiviral therapy can be beneficial, the optimal treatment regimen and duration remain under investigation.
Caveats and uncertainty
Despite promising results, several caveats exist. The efficacy of PEG-IFN-α is limited by its side effect profile and the low sustained virological response rate. Bulevirtide, though effective, is still under investigation for long-term safety and efficacy. Additionally, the high cost and limited availability of newer agents pose challenges for widespread implementation.
The heterogeneity of study populations and variations in HDV genotypes further complicate the generalizability of findings. Most studies have focused on genotype 1, which may not reflect outcomes in other genotypes prevalent in different regions. Moreover, the impact of antiviral therapy on long-term outcomes such as liver cirrhosis and hepatocellular carcinoma remains unclear.
How this may change practice
The introduction of bulevirtide and its potential combination with PEG-IFN-α represents a significant advancement in HDV management. Clinicians should consider these therapies for eligible patients, particularly those with advanced liver disease, while weighing the benefits against potential adverse effects and costs. As more data become available, treatment guidelines may evolve to incorporate these newer agents, potentially improving patient outcomes.
Continued research and real-world data are essential to refine treatment strategies, optimize patient selection, and assess long-term benefits. Clinicians should stay informed about emerging evidence and evolving guidelines to provide the best care for patients with HDV infection.